PERFORM AND VALIDATE YOUR PROCEDURES WITH CONFIDENCE
A primary focus during the early stages of research and drug development is to minimize future risk. As such, protein binding studies are often necessary to determine a drug’s efficacy. While regulatory guidance exists concerning protein-binding studies, detailed guidelines on how to perform and validate the procedures does not. This is where Worldwide shines and can play a vital role in your drug development program.
WORLDWIDE CLINICAL TRIALS: YOUR EXPERIENCED PROTEIN-BINDING STUDY PARTNER
Worldwide’s wealth of experience executing protein-binding studies coupled with the application of larger capacity, automated formats delivers high-quality, timely data at excellent value. We can accommodate both in vitro and ex vivo protein-binding studies (from animal species to man) utilizing plasma or tissue homogenates. Our procedures include the following:
- Automated processing
- Custom-built equilibrium dialysis device (500 µL volume) or other commercial plate-based systems
- Equilibrium dialysis
- Radioactive or non-radioactive compounds
- Ultracentrifugation
- Ultrafiltration
- Radio-labelled warfarin as a positive control
- Fully validated, high sensitivity LC-MS assays
- Standard Operating Procedures with QA oversight and review
AT WORLDWIDE, YOU ARE MORE THAN A MOLECULE
Are you ready to take your protein-binding study to the next level? Are you looking for a partner that can provide you with the operational excellence your program needs? Contact a Worldwide expert for support – no matter where you are on the path of drug development and research.
WORLDWIDE IS AN AWARD-WINNING, TOP-PERFORMING EARLY PHASE CRO
See how we rank amongst the world’s early phase contract research organizations.
